The mouse lethality test is the most sensitive method for confirming the diagnosis of infant botulism. Both Clostridium difficile and Clostridium botulinum produce heat-labile toxins which are lethal for mice and can be found in the feces of infants. These two toxins can be distinguished from one another in this assay when both are present in the same fecal specimen because they appear to be immunologically distinct toxins.
Infant botulism is a neuromuscular syndrome seen in children less than 1 year old and is characterized by progressive muscular weakness and hypotonia (1) . The pathophysiology of the disease is due to the production of Clostridium botulinum toxin in the gastrointestinal tract of infants (2) .
The definitive diagnosis of C. botulinum-induced disease is made by detection of botulinal toxin in filtrates prepared from feces of symptomatic infants (4) . This is done by using a mouse lethality test (MLT) which includes specific neutralization of botulinal toxin activity with polyvalent antitoxin to the different botulinal toxin types. At least one other clostridial species, Clostridium difficile, produces toxins in the gastrointestinal tract of infants which are lethal for mice (10) . Surveys of healthy infants have shown that this toxin was present in feces of between 25 to 60% of the infants studied (3, 8, 9) .
Recently a patient at our institution presented with clinical symptoms of infant botulism. Two fecal specimens obtained from this child produced lethality in mice which could not be neutralized by polyvalent botulinal antitoxin.
Further studies showed that this toxicity was due to C. difficile toxin. Because of the apparently high incidence of C. difficile toxin in feces of infants and its lethality for mice, we describe a methodology by which C. difficile toxin can be differentiated from botulinal toxin in the MLT. Assay for C. difficile toxin was done by using a tissue culture cytotoxicity and neutralization assay as previously described (7) . Stool filtrates were prepared by mixing stool samples with an equal volume of phosphate-buffered saline (pH 7.2), centrifuging this mixture at 8,500 x g for 10 min, and filtering the resulting supernatant through a 0.45 ,um filter (Acrodisc; Gelman Sciences, Inc., Ann Arbor, Mich.). These filtrates were placed on monolayers of MRC-5 cells, a human fibroblast cell line. The cells were examined at 12-h intervals for 48 h. Those filtrates which produced cytotoxicity in the tissue culture cells were then tested in a neutralization assay. Cytotoxic filtrates were mixed with a 1:10 dilution of normal goat serum, goat C. difficile antitoxin, or undiluted polyvalent (ABC-DEF) C. botulinum antitoxin and incubated for 30 min. These mixtures were applied to the cell monolayers, and they were examined for 48 h to observe whether the C. difficile or the C. botulinum antitoxin neutralized the cytotoxic effect produced in tissue culture cells by the stool filtrates.
Polyvalent C. botulinum antitoxin was obtained from the Biological Reagent Division, Centers for Disease Control, Atlanta, Ga. C. difficile antitoxin was purchased from Tracy Wilkins of the Virginia Polytechnic Institute and State University, Blacksburg, Va. (5).
Assay for botulinal toxin was done as described by Dowell et al. (4) . Briefly, the feces were mixed with an equal amount (weight to volume) of phosphate-gelatin buffer (0.2% gelatin and 0.4% dibasic sodium phosphate in distilled water adjusted to pH 6.2 with hydrochloric acid). The mixture was refrigerated at 4°C overnight to extract the toxin from the feces. The feces-buffer mixture was centrifuged at 8,500 x g for 10 min, and the supernatant was removed and assayed.
Four groups of three white mice (20 to 30 g) were inoculated for each fecal specimen. Each mouse in one group was injected intraperitoneally with 0.4 ml of untreated fecal supernatant.
Each mouse in another group was injected intra- They were assayed as already described except for the neutralization assay. For the neutralization assay, 2.0 ml of the toxin mixture was incubated with 0.5 ml of normal goat serum or with 0.25 ml of each serum as shown in Table 1 . These mixtures were incubated and then injected into groups of three mice as previously described. These mixtures were also assayed in the C. difficile cytotoxicity assay.
A fecal specimen from a patient with pseudomembranous colitis proven to be positive for C. difficile toxin with a toxin titer of 104 was used as a positive C. difficile toxin control in the assays. Two fecal specimens, one with previously confirmed botulinal toxin type A and the other with previously confirmed botulinal toxin type B, were used as positive botulinal toxin controls in the toxin assays.
A fecal specimen was obtained upon admission from a patient with suspected infant botulism and was submitted to one of our laboratories (R.E.B.) for determination of the presence of botulinal toxin. The specimen contained a heat-labile toxic component which could not be neutralized by polyvalent botulinal antitoxin even after diluting the feces 1:10 in phosphategelatin buffer (pH 6.2). A second specimen obtained 5 days after admission, was assayed for C. difficile toxin using a cytotoxicity assay. This assay was positive for C. difficile toxin, with a toxin titer of 104. Anaerobic culture for C. difficile using cycloserine-cefoxitin-fructose agar, a selective medium for C. difficile (6), was also positive. This specimen was also lethal in the MLT. The toxicity was heat labile and could not be neutralized by polyvalent botulinal antitoxin but was neutralized by antitoxin against C. difficile toxin (Table 1) .
Fecal specimens containing either botulinal toxin A or B alone or in combination with a specimen containing C. difficile toxin were then examined for activity and immunological crossreactivity in the two assay systems (Table 1) . Botulinal toxin A or B was inactive in the cytotoxicity assay. There was no cross neutralization between C. difficile antitoxin and either botulinal toxin in the MLT nor did polyvalent botulinal antitoxin neutralize C. difficile toxin in either assay. When botulinal toxin B and C. diJficile toxin were mixed, neutralization of the two toxins in the MLT was only accomplished when the mixture of the two toxins was preincubated with both specific antisera.
The MLT has proven to be the most sensitive method for laboratory diagnosis of C. botulinum intoxication (4) . Unfortunately, other toxins lethal for mice, such as endotoxin, and as reported here, C. difficile toxin, can be present in feces and interfere with the detection of C. botulinum toxin in this assay.
In three studies, C. difficile toxin has been found in the feces of between 25 and 60% of healthy infants (3, 8, 9) . Because of the apparent high incidence of this toxin in the feces of normal infants, it is surprising that no other cases of MLT interference caused by the toxin have been reported. It would seem appropriate that feces from patients who have the diagnosis of infant botulism should be screened for C. difficile toxin so that nonspecific toxicity in the MLT due to C. difficile toxin can be detected. In patients with C. difficile toxin in their stools, the MLT should include two more sets of mice, one group getting fecal supernatant incubated with C. difficile antitoxin before injection and another group receiving fecal supernatant incubated with polyvalent C. botulinum antitoxin and C. difficile antitoxin. Since we have shown in this report that there appears to be no cross-reaction between C. difficile toxin and polyvalent C. botulinum antitoxin or C. difficile antitoxin and botulinal toxin types A and B, the two most common toxin types associated with infant botulism (2), neutralization of the lethal effect of stool supernatants by C. difficile antitoxin alone would indicate that the lethal effect seen was due to C. difficile toxin. When both botulinal toxin and C. difficile toxin are present in a patient's feces, only those mice receiving stool supernatant neutralized by both C. botulinum and C. difficile antitoxin should survive (Table 1) .
